Group 1: Company Overview - Cidara Therapeutics (CDTX) currently has a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Group 2: Performance Metrics - CDTX shares have increased by 10.8% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 6.19% [5] - Over the past month, CDTX's price change is 11.63%, compared to the industry's 2.23% [5] - In the last quarter, CDTX shares increased by 5.39%, and over the past year, they have gained 76.29%, while the S&P 500 has moved -7.64% and 10.16% respectively [6] Group 3: Trading Volume - The average 20-day trading volume for CDTX is 162,652 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 4: Earnings Outlook - In the past two months, one earnings estimate for CDTX has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$14.39 to -$7.12 [9] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [9] Group 5: Conclusion - Considering all performance metrics and earnings outlook, CDTX is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [11]

Core Insights - Cidara Therapeutics will participate in The Citizens Life Sciences Conference on May 7, 2025, at 11:00 AM ET, with a presentation format and a webcast available [1] - The company will also engage in one-on-one investor meetings during the event [2] Company Overview - Cidara Therapeutics is focused on developing drug-Fc conjugates (DFCs) using its proprietary Cloudbreak platform, which combines targeted small molecules or peptides with a human antibody fragment [3] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose and has received Fast Track Designation from the FDA [3] - CD388 completed Phase 2b enrollment in December 2024, and the company has also developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024 [3]

Core Insights - Cidara Therapeutics will report its Q1 2025 financial results and operational highlights on May 8, 2025, after U.S. market close [1] - A conference call and webcast will be held at 5:00 PM Eastern Time to discuss the results and business updates [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies, including its lead candidate CD388, aimed at universal prevention of influenza [3] - CD388 received Fast Track Designation from the FDA in June 2023 and completed Phase 2b enrollment in December 2024 [3] - The company has also developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024 [3]

Core Insights - Elicio Therapeutics has appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, bringing extensive leadership experience from previous roles in biotechnology companies [1][2][3] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, particularly targeting high-prevalence cancers such as mKRAS-positive pancreatic and colorectal cancers [4] - The company aims to leverage its Amphiphile ("AMP") technology to enhance the education, activation, and amplification of cancer-specific T cells, promoting durable cancer immunosurveillance [4][8] Product Pipeline - Elicio's lead product candidate, ELI-002, is an off-the-shelf vaccine targeting common KRAS mutations, which are responsible for approximately 25% of all solid tumors [4][7] - ELI-002 is currently being studied in a Phase 1/2 clinical trial (AMPLIFY-7P) for patients with mKRAS-positive pancreatic cancer who are at high risk of relapse [7] - The company also has additional candidates in its pipeline, including ELI-007 and ELI-008, targeting BRAF-driven cancers and p53 hotspot mutations, respectively [4] Technology Platform - The AMP platform is designed to deliver immunotherapeutics directly to lymph nodes, enhancing immune responses and potentially leading to more effective cancer treatments [8][10] - Elicio's technology has shown promise in preclinical models, indicating that lymph node-specific engagement can drive stronger and more durable therapeutic immune responses [10]

Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024 REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CIDARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1537286 (State or other jurisdiction of incorporation or organization) 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 (858) 752-6170 (Address, including zip ...